New Risk • May 30
New major risk - Revenue and earnings growth Earnings have declined by 66% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 66% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩30.5b market cap, or US$20.2m). Announcement • Mar 17
Genolution Inc., Annual General Meeting, Mar 27, 2026 Genolution Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South Korea Announcement • Mar 08
Genolution Inc., Annual General Meeting, Mar 28, 2025 Genolution Inc., Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 14, magokjungang 8-ro, gangseo-gu, seoul South Korea New Risk • Nov 14
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended September 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2023 fiscal period end). Revenue has declined by 78% over the past year. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (₩44.5b market cap, or US$31.7m). New Risk • Aug 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₩86.0b market cap, or US$64.6m). New Risk • Jun 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 26% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (₩73.9b market cap, or US$53.5m). Announcement • Jul 12
Genolution Inc. (KOSDAQ:A225220) announces an Equity Buyback for KRW 2,000 million worth of its shares. Genolution Inc. (KOSDAQ:A225220) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its own shares pursuant to a contract with Hana Securities. The purpose of the program is enhancement of shareholder's value. The program will expire on January 9, 2024. As of July 9, 2023, the company had 656,993 treasury shares within scope available for dividend and no shares in treasury through other repurchase. Valuation Update With 7 Day Price Move • May 16
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to ₩4,785, the stock trades at a trailing P/E ratio of 6.4x. Average trailing P/E is 27x in the Life Sciences industry in South Korea. Total returns to shareholders of 35% over the past three years. Upcoming Dividend • Dec 21
Inaugural dividend of ₩200 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 06 April 2023. This is the first dividend for Genolution since going public. The average dividend yield among industry peers is 0.7%. Announcement • Oct 06
Genolution Inc. (KOSDAQ:A225220) announces an Equity Buyback for KRW 2,000 million worth of its shares. Genolution Inc. (KOSDAQ:A225220) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 million worth of its own shares pursuant to a contract with Shinyoung Securities. The purpose of the program is enhancement of shareholder's value. The program will expire on April 5, 2023. As of October 5, 2022, the company had 516,512 treasury shares within scope available for dividend and no shares in treasury through other repurchase. Upcoming Dividend • Sep 22
Inaugural dividend of ₩200 per share Eligible shareholders must have bought the stock before 29 September 2022. Payment date: 31 October 2022. This is the first dividend for Genolution since going public. The average dividend yield among industry peers is 0.7%. Valuation Update With 7 Day Price Move • Jul 14
Investor sentiment improved over the past week After last week's 20% share price gain to ₩14,600, the stock trades at a trailing P/E ratio of 4x. Average trailing P/E is 29x in the Life Sciences industry in South Korea. Total returns to shareholders of 503% over the past three years. Valuation Update With 7 Day Price Move • Nov 29
Investor sentiment improved over the past week After last week's 17% share price gain to ₩15,550, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 398% over the past three years. Reported Earnings • Nov 17
Third quarter 2021 earnings released: EPS ₩858 (vs ₩1,420 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and revenues, although profit margins were improved. Third quarter 2021 results: Revenue: ₩17.3b (down 39% from 3Q 2020). Net income: ₩8.18b (down 34% from 3Q 2020). Profit margin: 47% (up from 44% in 3Q 2020). The increase in margin was driven by lower expenses. Valuation Update With 7 Day Price Move • Oct 06
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩13,400, the stock trades at a trailing P/E ratio of 2.7x. Average trailing P/E is 26x in the Life Sciences industry in South Korea. Total returns to shareholders of 285% over the past three years. Valuation Update With 7 Day Price Move • Jul 08
Investor sentiment improved over the past week After last week's 27% share price gain to ₩20,900, the stock trades at a trailing P/E ratio of 2x. Average trailing P/E is 30x in the Life Sciences industry in South Korea. Total returns to shareholders of 415% over the past three years. Announcement • Jun 09
Genolution Inc. announced that it has received KRW 5 billion in funding On June 8, 2021, Genolution Inc. closed the transaction. Announcement • Jun 05
Genolution Inc. announced that it expects to receive KRW 5 billion in funding Genolution Inc. (KOSDAQ:A225220) announced a private placement of non-guaranteed private convertible bonds for gross proceeds of KRW 5,000,000,000 on June 4, 2021. The transaction will involve participation from new investors including trustee funds 1, 2 managed by KB Securities Co., Ltd for KRW 1,000,000,000 and trustee fund 3 managed by NH Investment & Securities Co., Ltd for KRW 4,000,000,000. The bonds were issued at an interest rate of 1% and maturity rate of 1%.The bonds will be fully convertible into 315,417 common shares of the company at a fixed conversion price of KRW 15,852 per share between June 8, 2022 and May 8, 2026. The bonds will mature on June 08, 2026. The subscription date for the bonds is May 20, 2021 and payment date for the bonds is June 08, 2021. The transaction has been approved by the board of directors of the company. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment improved over the past week After last week's 17% share price gain to ₩17,850, the stock trades at a trailing P/E ratio of 2.2x. Average trailing P/E is 72x in the Life Sciences industry in South Korea. Total returns to shareholders of 331% over the past three years. Is New 90 Day High Low • Mar 10
New 90-day low: ₩24,550 The company is down 10.0% from its price of ₩27,300 on 10 December 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 15% over the same period. Is New 90 Day High Low • Jan 29
New 90-day low: ₩24,800 The company is down 36% from its price of ₩38,600 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 23% over the same period. Is New 90 Day High Low • Nov 24
New 90-day low: ₩25,800 The company is down 26% from its price of ₩35,050 on 27 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 1.0% over the same period. Is New 90 Day High Low • Nov 03
New 90-day high: ₩43,600 The company is up 4.0% from its price of ₩41,750 on 05 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 4.0% over the same period. Announcement • Jul 18
Genolution Inc. has completed a Follow-on Equity Offering in the amount of KRW 11.536 billion. Genolution Inc. has completed a Follow-on Equity Offering in the amount of KRW 11.536 billion.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 824,000
Price\Range: KRW 14000
Discount Per Security: KRW 840
Transaction Features: ESOP Related Offering 
